Ernexa Therapeutics Inc. Accrued Liabilities, Current
Ernexa Therapeutics Inc. (ERNA) had Accrued Liabilities, Current of $1.02 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current › Accrued Liabilities, Current
us-gaap:AccruedLiabilitiesCurrent · last filed 2026-08-06
- 2026-06-30: Accrued Liabilities, Current $1.02M.
- 2026-03-31: Accrued Liabilities, Current $1.48M.
- 2025-12-31: Accrued Liabilities, Current $898.00K.
- 2025-09-30: Accrued Liabilities, Current $859.00K.
| Period end | Accrued Liabilities, Current | Accrued Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $1.02M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $1.48M 10-Q · filed 2026-05-11 | |
| 2025-12-31 | $898.00K 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $859.00K 10-Q · filed 2025-11-07 | |
| 2025-06-30 | $938.00K 10-Q · filed 2025-08-13 | |
| 2025-03-31 | $1.35M 10-Q · filed 2025-05-07 | |
| 2024-12-31 | $1.01M 10-K · filed 2026-03-13 | |
| 2024-09-30 | $1.17M 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $2.39M 10-Q · filed 2024-08-13 | |
| 2024-03-31 | $1.87M 10-Q · filed 2024-05-14 | |
| 2023-12-31 | $1.89M 10-K · filed 2025-03-12 | |
| 2023-09-30 | $5.02M 10-Q · filed 2023-11-13 | |
| 2023-06-30 | $2.11M 10-Q · filed 2023-08-11 | |
| 2023-03-31 | $3.63M 10-Q · filed 2023-08-11 | $2.01M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $3.63M 10-K · filed 2024-03-14 | |
| 2022-09-30 | $3.23M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $3.82M 10-Q · filed 2022-08-11 | |
| 2022-03-31 | $2.38M 10-Q · filed 2022-07-01 | |
| 2021-12-31 | $1.25M 10-K · filed 2023-03-20 | |
| 2021-09-30 | $2.13M 10-Q · filed 2021-11-12 | |
| 2021-06-30 | $1.92M 10-Q · filed 2021-08-13 | |
| 2021-03-31 | $1.16M 10-Q · filed 2021-05-17 | |
| 2020-12-31 | $1.05M 10-K/A · filed 2022-07-01 | $238.00K 10-K · filed 2021-03-11 |
| 2020-09-30 | $490.00K 10-Q · filed 2020-11-13 | |
| 2020-06-30 | $385.00K 10-Q · filed 2020-08-07 | |
| 2020-03-31 | $237.00K 10-Q · filed 2020-05-20 | |
| 2019-12-31 | $490.00K 10-K · filed 2021-03-11 | |
| 2019-09-30 | $322.00K 10-Q · filed 2019-11-01 | |
| 2019-06-30 | $372.00K 10-Q · filed 2019-08-12 | |
| 2019-03-31 | $416.00K 10-Q · filed 2019-05-14 | |
| 2018-12-31 | $444.00K 10-K · filed 2020-03-19 | |
| 2018-09-30 | $792.00K 10-Q · filed 2018-11-09 | |
| 2018-06-30 | $581.00K 10-Q · filed 2018-08-06 | |
| 2018-03-31 | $498.00K 10-Q · filed 2018-05-11 | |
| 2017-12-31 | $418.00K 10-K · filed 2019-03-22 | |
| 2017-09-30 | $711.00K 10-Q · filed 2017-11-08 | |
| 2017-06-30 | $438.00K 10-Q · filed 2017-08-04 | |
| 2017-03-31 | $561.00K 10-Q · filed 2017-05-04 | |
| 2016-12-31 | $697.00K 10-K · filed 2018-03-09 | |
| 2016-09-30 | $529.00K 10-Q · filed 2016-11-09 | |
| 2016-06-30 | $529.00K 10-Q · filed 2016-08-04 | |
| 2016-03-31 | $647.00K 10-Q · filed 2016-05-09 | |
| 2015-12-31 | $670.00K 10-K · filed 2017-03-09 | |
| 2015-09-30 | $715.00K 10-Q · filed 2015-11-09 | |
| 2015-06-30 | $859.00K 10-Q · filed 2015-08-10 | |
| 2015-03-31 | $1.00M 10-Q · filed 2015-05-08 | |
| 2014-12-31 | $969.00K 10-K · filed 2016-03-15 | |
| 2014-09-30 | $731.00K 10-Q · filed 2014-11-07 | |
| 2014-06-30 | $730.00K 10-Q · filed 2014-08-14 | |
| 2014-03-31 | $736.00K 10-Q · filed 2014-05-15 | |
| 2013-12-31 | $660.00K 10-K · filed 2015-03-27 | |
| 2012-12-31 | $538.00K 10-K · filed 2014-03-31 | |
| 2011-12-31 | $801.00K 10-K · filed 2013-03-29 | |
| 2010-12-31 | $451.00K 10-K · filed 2012-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |